FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints
Watch Boston Scientific's latest callBoston Scientific (NYSE:BSX) Q3 2026 Earnings Call · Replay · Oct 28Read the transcript of Boston Scientific (NYSE:BSX) Q3 2026 Earnings CallThe original release is unavailable here.
Boston Scientific Corporation on 6ix
Earlier from Boston Scientific
- Boston Scientific enters into $2 billion accelerated share repurchase agreement
- Boston Scientific announces strategic investment in MiRus LLC
- FDA issues most serious recall for certain pacemaker devices by Boston Scientific
- Penumbra, Inc. Reports First Quarter 2026 Financial Results
- Boston Scientific announces participation in Bernstein's 42nd Annual Strategic Decisions Conference and conference call discussing second quarter 2026 results
Later from Boston Scientific
- Boston Scientific: Four things to know about our acquisition of Valencia Technologies
- New report identifies opportunities to help more patients in Asia Pacific benefit from advances in AFib care
- Boston Scientific announces results for second quarter 2026
- Boston Scientific announces participation in Wells Fargo 21st Annual Healthcare Conference and conference call discussing third quarter 2026 results
- Boston Scientific appoints Joseph M. Fitzgerald Executive Vice President and Chief Operating Officer
Follow Boston Scientific into a list and get an email when it puts out news.
Follow Boston Scientific